

# Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

<https://marketpublishers.com/r/V80CC8A1DF71EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: V80CC8A1DF71EN

## Abstracts

The 7 major vasomotor symptoms markets reached a value of US\$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.2% during 2024-2034.

The Vasomotor Symptoms Market has been comprehensively analyzed in IMARC's new report titled "Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Vasomotor symptoms are temperature dysfunctions that occur due to changes in gonadal hormones in females. These symptoms occur due to the constriction or dilation of blood vessels. These symptoms can also be referred to as menopausal symptoms, for which women seek treatment during menopause most often. At around the age of 40, estrogen and progesterone levels start to reduce in females. Therefore, as the females get older, a female may experience vasomotor symptoms. These hormonal fluctuations affect the mechanisms that control blood pressure and temperature control, and females may experience different symptoms. Vasomotor symptoms include hot flashes, night sweats, heart palpitations, and changes in blood pressure. Hormone therapy is the most effective treatment for vasomotor symptoms and other menopausal symptoms. Estrogens are known as potent neuromodulators of several neuronal circuits throughout the central nervous system. Changing estrogen levels during menopause may impact multiple components in maintaining temperature homeostasis. Similarly, for the drug discovery process, understanding the cause of thermoregulatory dysfunction and mechanisms involved in temperature regulation help specialists to introduce effective drugs.

The rising prevalence of menopausal and post-menopausal symptoms owing to the adoption of unhealthy eating habits and sedentary lifestyles is primarily driving the

vasomotor symptoms market. In addition to this, the ongoing development of several treatment options that target the brain's thermostat to reduce the incidence of vasomotor symptoms, such as hot flashes, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of non-hormonal alternatives, such as selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors, among patients with a history of breast cancer is also bolstering the market growth. Apart from this, the escalating demand for cognitive behavior therapy for treating complications associated with vasomotor symptoms, such as sleep disturbances and low-productivity levels in professional environments, is further creating a positive outlook for the market. This nonpharmacologic treatment aids in modifying dysfunctional emotions, behaviors, and thoughts that enhance personal coping strategies. Additionally, several governing bodies, along with non-governmental organizations (NGOs), are supporting various health education campaigns to address the stigma and associated silence pertaining to symptoms of menopause. This, in turn, is also propelling the adoption of drugs and medications for the treatment of vasomotor symptoms. Apart from this, the introduction of various innovative approaches for treating distressing vasomotor symptoms with the lowest effective dose in the shortest duration is expected to drive the vasomotor symptoms market in the coming years.

IMARC Group's new report "Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Vasomotor Symptoms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Vasomotor Symptoms market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Vasomotor Symptoms across the seven major markets. According to the report the United States has the largest patient pool for Vasomotor Symptoms and also represents the largest market for Vasomotor Symptoms treatment. Furthermore, the current Vasomotor Symptoms treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Vasomotor Symptoms market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

## Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

## Analysis Covered Across Each Country

Historical, Current and Future Epidemiology Scenario

Historical, Current and Future Performance of the Vasomotor Symptoms Market

Historical, Current and Future Performance of Various Therapeutic Categories in the Vasomotor Symptoms Market

Sales of Various Drugs Across the Vasomotor Symptoms Market

Reimbursement Scenario in the Vasomotor Symptoms Market

In-Market and Pipeline Drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Vasomotor Symptoms marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

## Clinical Trial Results

### Drug Uptake and Market Performance

#### Key Questions Answered in this Report:

#### Market Insights

How has the Vasomotor Symptoms market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?

What was the country-wise size of the Vasomotor Symptoms market across the seven major markets in 2023 and how will it look like in 2034?

What is the growth rate of the Vasomotor Symptoms market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the Vasomotor Symptoms market?

#### Epidemiology Insights

What is the size of the Vasomotor Symptoms patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) of Vasomotor Symptoms across the seven major markets?

What are the key factors driving the epidemiological trend of Vasomotor Symptoms?

What will be the growth rate of Vasomotor Symptoms patients across the seven major markets?

#### Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed Vasomotor Symptoms drugs and what are their market performance?

What are the key pipeline Vasomotor Symptoms drugs and how are they expected to perform in the coming years?

How safe are the current marketed Vasomotor Symptoms drugs and what are their efficacies?

How safe are the late-stage pipeline Vasomotor Symptoms drugs and what are their efficacies?

What are the current treatment guidelines for Vasomotor Symptoms drugs across the seven major markets?

Who are the key companies in the Vasomotor Symptoms market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Vasomotor Symptoms market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 VASOMOTOR SYMPTOMS - INTRODUCTION

- 4.1 Overview
- 4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.3 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.4 Competitive Intelligence

### 5 VASOMOTOR SYMPTOMS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 VASOMOTOR SYMPTOMS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets

- 7.2.1 Epidemiology Scenario (2018-2023)
- 7.2.2 Epidemiology Forecast (2024-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)

## **8 VASOMOTOR SYMPTOMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Vasomotor Symptoms Guidelines, Management and Treatment
- 8.2 Vasomotor Symptoms Treatment Algorithm

## **9 VASOMOTOR SYMPTOMS - UNMET NEEDS**

## **10 VASOMOTOR SYMPTOMS - KEY ENDPOINTS OF TREATMENT**

## **11 VASOMOTOR SYMPTOMS - MARKETED PRODUCTS**

- 11.1 List of Vasomotor Symptoms Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name - Company Name
    - 11.1.1.1 Drug Overview

- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 VASOMOTOR SYMPTOMS - PIPELINE DRUGS**

### 12.1 List of Vasomotor Symptoms Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name - Company Name
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status

Kindly note that complete list of pipeline drugs has been provided in the report.

## **13. VASOMOTOR SYMPTOMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14 VASOMOTOR SYMPTOMS - MARKET SCENARIO**

- 14.1 Market Scenario - Key Insights
- 14.2 Market Scenario - Top 7 Markets
  - 14.2.1 Vasomotor Symptoms - Market Size
    - 14.2.1.1 Market Size (2018-2023)
    - 14.2.1.2 Market Forecast (2024-2034)
  - 14.2.2 Vasomotor Symptoms - Market Size by Therapies
    - 14.2.2.1 Market Size by Therapies (2018-2023)
    - 14.2.2.2 Market Forecast by Therapies (2024-2034)
- 14.3 Market Scenario - United States
  - 14.3.1 Vasomotor Symptoms - Market Size
    - 14.3.1.1 Market Size (2018-2023)
    - 14.3.1.2 Market Forecast (2024-2034)
  - 14.3.2 Vasomotor Symptoms - Market Size by Therapies
    - 14.3.2.1 Market Size by Therapies (2018-2023)
    - 14.3.2.2 Market Forecast by Therapies (2024-2034)
  - 14.3.3 Vasomotor Symptoms - Access and Reimbursement Overview
- 14.4 Market Scenario - Germany



- 14.4.1 Vasomotor Symptoms - Market Size
  - 14.4.1.1 Market Size (2018-2023)
  - 14.4.1.2 Market Forecast (2024-2034)
- 14.4.2 Vasomotor Symptoms - Market Size by Therapies
  - 14.4.2.1 Market Size by Therapies (2018-2023)
  - 14.4.2.2 Market Forecast by Therapies (2024-2034)
- 14.4.3 Vasomotor Symptoms - Access and Reimbursement Overview
- 14.5 Market Scenario - France
  - 14.5.1 Vasomotor Symptoms - Market Size
    - 14.5.1.1 Market Size (2018-2023)
    - 14.5.1.2 Market Forecast (2024-2034)
  - 14.5.2 Vasomotor Symptoms - Market Size by Therapies
    - 14.5.2.1 Market Size by Therapies (2018-2023)
    - 14.5.2.2 Market Forecast by Therapies (2024-2034)
  - 14.5.3 Vasomotor Symptoms - Access and Reimbursement Overview
- 14.6 Market Scenario - United Kingdom
  - 14.6.1 Vasomotor Symptoms - Market Size
    - 14.6.1.1 Market Size (2018-2023)
    - 14.6.1.2 Market Forecast (2024-2034)
  - 14.6.2 Vasomotor Symptoms - Market Size by Therapies
    - 14.6.2.1 Market Size by Therapies (2018-2023)
    - 14.6.2.2 Market Forecast by Therapies (2024-2034)
  - 14.6.3 Vasomotor Symptoms - Access and Reimbursement Overview
- 14.7 Market Scenario - Italy
  - 14.7.1 Vasomotor Symptoms - Market Size
    - 14.7.1.1 Market Size (2018-2023)
    - 14.7.1.2 Market Forecast (2024-2034)
  - 14.7.2 Vasomotor Symptoms - Market Size by Therapies
    - 14.7.2.1 Market Size by Therapies (2018-2023)
    - 14.7.2.2 Market Forecast by Therapies (2024-2034)
  - 14.7.3 Vasomotor Symptoms - Access and Reimbursement Overview
- 14.8 Market Scenario - Spain
  - 14.8.1 Vasomotor Symptoms - Market Size
    - 14.8.1.1 Market Size (2018-2023)
    - 14.8.1.2 Market Forecast (2024-2034)
  - 14.8.2 Vasomotor Symptoms - Market Size by Therapies
    - 14.8.2.1 Market Size by Therapies (2018-2023)
    - 14.8.2.2 Market Forecast by Therapies (2024-2034)
  - 14.8.3 Vasomotor Symptoms - Access and Reimbursement Overview

## 14.9 Market Scenario - Japan

### 14.9.1 Vasomotor Symptoms - Market Size

#### 14.9.1.1 Market Size (2018-2023)

#### 14.9.1.2 Market Forecast (2024-2034)

### 14.9.2 Vasomotor Symptoms - Market Size by Therapies

#### 14.9.2.1 Market Size by Therapies (2018-2023)

#### 14.9.2.2 Market Forecast by Therapies (2024-2034)

### 14.9.3 Vasomotor Symptoms - Access and Reimbursement Overview

## **15 VASOMOTOR SYMPTOMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **16 VASOMOTOR SYMPTOMS MARKET - SWOT ANALYSIS**

### 16.1 Strengths

### 16.2 Weaknesses

### 16.3 Opportunities

### 16.4 Threats

## **17 APPENDIX**

## I would like to order

Product name: Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/V80CC8A1DF71EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V80CC8A1DF71EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

